Ramprakash Devadoss

Dr. Ramprakash Devadoss

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GDGagandeep Dhillon
Gagandeep Dhillon
VBVenkata Buddhavarapu
Venkata Buddhavarapu
HGHarpreet Grewal
Harpreet Grewal
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
Rahul KashyapRahul Kashyap
Rahul Kashyap
Hydrogen-rich water (HRW) has emerged as a novel approach in the field of health and wellness. It is believed to have therapeutic antioxidant properties that can neutralize harmful free radicals in the human body. It has also been shown to be beneficial in mitigating oxidative stress-induced damage through its anti-inflammatory and anti-apoptotic pathways. We aim to conduct a systematic review to evaluate the potential benefits of hydrogen-rich water. The review protocol was uploaded on PROSPERO. After the initial search criteria, the articles were reviewed by two blinded investigators, and a total of 25 articles were included in the systematic review. The potential benefits of hydrogen-rich water on various aspects of health, including exercise capacity, physical endurance, liver function, cardiovascular disease, mental health, COVID-19, oxidative stress, and anti-aging research, are a subject of growing interest and ongoing research. Although preliminary results in clinical trials and studies are encouraging, further research with larger sample sizes and rigorous methodologies is needed to substantiate these findings. Current research needs to fully explain the mechanisms behind the potential benefits of hydrogen-rich water. Continued scientific exploration will provide valuable insights into the potential of hydrogen-rich water as an adjunctive therapeutic approach in the future.

1 January 2024 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
PSPranjal Sharma
Pranjal Sharma
VBVenkata Buddhavarapu
Venkata Buddhavarapu
GDGagandeep Dhillon
Gagandeep Dhillon
RVRam Kishun Verma
Ram Kishun Verma
RDRamprakash Devadoss
Ramprakash Devadoss
Rahul KashyapRahul Kashyap
Rahul Kashyap
Introduction: As obesity evolves as a global pandemic along with diabetes mellitus, the development and use of drugs used to treat the same is booming. The latest among them is Glucagon-like peptide-1 receptor agonists (GLP-1 RA). Along with the use, the incidence of adverse events has become more common. It becomes imperative to focus on severe adverse effects for this reason. Although mentioned, there has been no detailed discussions regarding severe adverse effects and associations are also unclear regarding some. Methods: A systematic search was conducted for full length manuscripts published in the last two decades. We focused on papers that listed severe adverse effects with some details. Studies involving the pediatric population and patients on multiple oral antihyperglycemics were excluded. Statistical Analysis: Data analysis was performed using Revman 5.0 version. Results: The analysis of GLP-1RA therapies across 8 studies, involving 4422 subjects, indicates varying rates of Serious Adverse Events (SAE). Semaglutide demonstrates an SAE incidence of 8.9%, compared to 6.2% with Liraglutide, though not statistically significant. The analysis indicated Semaglutide had an elevated SAE risk with an Odds ratio (OR)=1.27, but did not have statistical significance (95% CI 0.84-1.91, p=0.26, I2=63%). Similarly, patients in the Liraglutide group had an increased risk of SAE with OR of 1.19 (95%CI 0.91-1.55, p=0.86, I2=40%) but this did not reach statistical significance. In both Semaglutide and Liraglutide, gastrointestinal adverse events predominate, with pancreatitis and neoplasm incidence noted, albeit without a clear causal relationship established. Discontinuation rates due to adverse effects were 10.3% for Semaglutide versus 3.1% for placebo, and 8.3% for Liraglutide versus 3.3% for placebo. The classification of these incidents as SAEs was unclear, and hence, they were excluded from statistical analysis. Conclusion: Severe adverse effects with GLP-1 RA are not uncommon and warrant further close monitoring when patients are started on the treatment. Further studies are required to analyze the difference between the adverse effect profiles of each drug and to assess whether or not each of the severe adverse effects is dose dependent.

25 December 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
GDGagandeep Dhillon
Gagandeep Dhillon
VBVenkata Buddhavarapu
Venkata Buddhavarapu
HGHarpreet Grewal
Harpreet Grewal
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
Rahul KashyapRahul Kashyap
Rahul Kashyap
Hydrogenated water has emerged as a novel approach in the field of health and wellness. It is be-lieved to have potent antioxidant properties that can neutralize harmful free radicals in the hu-man body. It has also been shown to be beneficial in mitigating oxidative stress-induced damage through its anti-inflammatory and anti-apoptotic pathways. We aim to conduct a systematic re-view to evaluate the potential benefits of hydrogenated water. The review protocol was uploaded on PROSPERO. After the initial search criteria, the articles were reviewed by two blinded inves-tigators, and a total of 25 articles were included in the systematic review. The potential benefits of hydrogenated water on various aspects of health, including exercise capacity, physical endurance, liver function, cardiovascular disease, mental health, COVID-19, oxidative stress, and anti-aging research, are a subject of growing interest and ongoing research. Although preliminary results in clinical trials and studies are encouraging, further research with larger sample sizes and rigor-ous methodologies is needed to substantiate these findings. Current research needs to fully ex-plain the mechanisms behind the potential benefits of hydrogenated water. Continued scientific exploration will provide valuable insights into the potential of hydrogenated water as an adjunc-tive therapeutic approach in the future.